Eupraxia Pharmaceuticals Inc. (EPRX)
EPRX moved a median of -0.42% 30 minutes after news, and -0.34% by the close. How EPRX actually reacts to news — the realized, point-in-time move the market made, measured across 198 labeled events over the last three years with zero look-ahead.
EPRX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 37% | 147 |
| 30-min | -0.42% | 35% | 173 |
| 60-min | -0.73% | 40% | 187 |
| to close | -0.34% | 44% | 196 |
| Middle 50% of EPRX reactions | -3.04% to +1.02% |
|---|---|
| Median reaction (30-min) | -0.42% |
| Measured reactions | 198 |
Half of all Eupraxia Pharmaceuticals Inc. news events land between -3.04% and +1.02% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How EPRX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 23 | +1.65% | 74% | +1.67% |
| Rating reiterations | 12 | -0.19% | 42% | -0.40% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how EPRX ranks against every other measured name →
That’s how EPRX usually reacts — get an email when it moves on news →Email me when EPRX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to EPRX's baseline. Nothing else.
Recent EPRX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic Esophagitis | Press release | GlobeNewswire | -1.51% | +2.58% | |
| Form 6-K EUPRAXIA PHARMACEUTICALS For: Oct 15 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +1.04% | |
| Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences | Press release | GlobeNewswire | -0.33% | -2.36% | |
| Form 6-K EUPRAXIA PHARMACEUTICALS For: Oct 09 | SEC filing · Form 6-K | SEC EDGAR | -0.33% | -2.36% | |
| Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis | Press release | GlobeNewswire | -0.96% | +9.24% | |
| Form 6-K EUPRAXIA PHARMACEUTICALS For: Sep 30 | SEC filing · Form 6-K | SEC EDGAR | -0.96% | +9.24% | |
| Eupraxia Pharmaceuticals Completes Transfer to the Nasdaq Global Select Market and Announces Participation in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.17% | -2.02% | |
| Form 6-K EUPRAXIA PHARMACEUTICALS For: Sep 08 | SEC filing · Form 6-K | SEC EDGAR | +0.17% | -2.02% | |
| Form SUPPL EUPRAXIA PHARMACEUTICALS | SEC filing · Form SUPPL | SEC EDGAR | +5.47% | +16.41% | |
| Form EFFECT EUPRAXIA PHARMACEUTICALS | SEC filing · Form EFFECT | SEC EDGAR | +0.14% | +1.50% | |
| Form F-10/A EUPRAXIA PHARMACEUTICALS | SEC filing · Form F-10 | SEC EDGAR | -0.35% | -0.35% | |
| Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients | Press release | GlobeNewswire | -0.45% | -0.45% | |
| Form 6-K EUPRAXIA PHARMACEUTICALS For: Aug 13 | SEC filing · Form 6-K | SEC EDGAR | -0.45% | -0.45% | |
| Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results | Press release | GlobeNewswire | -2.70% | -2.70% | |
| Form 6-K EUPRAXIA PHARMACEUTICALS For: Aug 11 | SEC filing · Form 6-K | SEC EDGAR | -2.70% | -2.70% | |
| Form F-10 EUPRAXIA PHARMACEUTICALS | SEC filing · Form F-10 | SEC EDGAR | -0.31% | +3.58% | |
| Form 6-K EUPRAXIA PHARMACEUTICALS For: Jul 15 | SEC filing · Form 6-K | SEC EDGAR | +0.23% | +1.32% | |
| Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth | Press release | GlobeNewswire | +1.92% | +1.28% | |
| Form 6-K EUPRAXIA PHARMACEUTICALS For: Jul 13 | SEC filing · Form 6-K | SEC EDGAR | +1.92% | +1.28% | |
| Eupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and Commercialization | Press release | GlobeNewswire | +0.46% | +2.78% | |
| Form 6-K EUPRAXIA PHARMACEUTICALS For: Jul 07 | SEC filing · Form 6-K | SEC EDGAR | -0.08% | +5.01% | |
| Form 6-K EUPRAXIA PHARMACEUTICALS For: Jun 19 | SEC filing · Form 6-K | SEC EDGAR | -0.19% | +2.27% | |
| Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders | Press release | GlobeNewswire | -0.08% | +1.84% | |
| Form 6-K EUPRAXIA PHARMACEUTICALS For: Jun 18 | SEC filing · Form 6-K | SEC EDGAR | — | -1.80% | |
| Form 6-K EUPRAXIA PHARMACEUTICALS For: May 28 | SEC filing · Form 6-K | SEC EDGAR | — | -1.80% | |
| Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference | Press release | GlobeNewswire | — | +3.51% | |
| Form 6-K EUPRAXIA PHARMACEUTICALS For: May 28 | SEC filing · Form 6-K | SEC EDGAR | -0.41% | -3.93% | |
| Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results | Press release | GlobeNewswire | -0.26% | -3.58% | |
| Form 6-K EUPRAXIA PHARMACEUTICALS For: May 12 | SEC filing · Form 6-K | SEC EDGAR | -0.26% | -3.58% | |
| Eupraxia Pharmaceuticals’ First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week | Press release | GlobeNewswire | +0.00% | +3.69% | |
| Form 6-K EUPRAXIA PHARMACEUTICALS For: May 06 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +3.69% | |
| Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW) | Press release | GlobeNewswire | — | -3.07% | |
| Form 6-K EUPRAXIA PHARMACEUTICALS For: May 05 | SEC filing · Form 6-K | SEC EDGAR | — | -3.07% | |
| Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer | Press release | GlobeNewswire | +1.54% | -4.99% | |
| Form 6-K EUPRAXIA PHARMACEUTICALS For: May 01 | SEC filing · Form 6-K | SEC EDGAR | +1.54% | -4.99% | |
| Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting | Press release | GlobeNewswire | +0.00% | -0.28% | |
| Form 6-K EUPRAXIA PHARMACEUTICALS For: Apr 22 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -0.28% | |
| Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis | Press release | GlobeNewswire | +2.97% | -5.26% | |
| Form 6-K EUPRAXIA PHARMACEUTICALS For: Apr 21 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -7.39% | |
| Form 6-K EUPRAXIA PHARMACEUTICALS For: Apr 14 | SEC filing · Form 6-K | SEC EDGAR | +4.06% | +1.93% | |
| Eupraxia Pharmaceuticals to Present at Upcoming Investor Conferences | Press release | GlobeNewswire | +1.43% | +2.72% | |
| Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis | Press release | GlobeNewswire | +3.53% | +2.99% | |
| Form 6-K EUPRAXIA PHARMACEUTICALS For: Mar 17 | SEC filing · Form 6-K | SEC EDGAR | +3.53% | +2.99% | |
| Form 40-F EUPRAXIA PHARMACEUTICALS For: Dec 31 | SEC filing · Form 40-F | SEC EDGAR | +0.00% | -1.34% | |
| Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results | Press release | GlobeNewswire | +0.00% | -1.34% | |
| Form 6-K EUPRAXIA PHARMACEUTICALS For: Feb 23 | SEC filing · Form 6-K | SEC EDGAR | — | -0.62% | |
| Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option | Press release | GlobeNewswire | -0.70% | -0.82% | |
| Form 6-K EUPRAXIA PHARMACEUTICALS For: Feb 19 | SEC filing · Form 6-K | SEC EDGAR | +2.95% | +4.55% | |
| Form 6-K EUPRAXIA PHARMACEUTICALS For: Feb 20 | SEC filing · Form 6-K | SEC EDGAR | -0.59% | -0.12% | |
| Form SUPPL EUPRAXIA PHARMACEUTICALS | SEC filing · Form SUPPL | SEC EDGAR | +2.95% | +4.55% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the EPRX section they belong to.
Where else EPRX is measured.
EPRX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Eupraxia Pharmaceuticals Inc.'s median reaction calculated?
Every labeled EPRX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 198 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 35% of EPRX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does EPRX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.